NCSLC Highlights 2012 - Part 1

 

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module provide you with an update on data from latest clinical studies in patients with non-small cell lung cancer (NSCLC) on integration of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy (1-not at all; 5-a lot)

2. Did your undertaking of this E-Learning module provide you with an update on recent clinical studies on first-line EGFR TKI and biomarkers in EGFR mutation positive NSCLC patients (1-not at all; 5-a lot)

3. Did your undertaking of this E-Learning module provide you with an update on clinical studies that tested strategies on overcoming EGFR TKI resistance in EGFR mutation positive NSCLC patients (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: